Abstract| Volume 116, P74, December 2022

P002Abortion pills for future use: Who is receiving advanced provision of medications to induce abortion?

      This paper is only available as a PDF. To read, Please Download here.


      To describe sociodemographic characteristics of patients requesting abortion medications for future use from an online provider.


      This descriptive study of requests for advanced provision of mifepristone and misoprostol from Aid Access between August and December 2021 used patient records from nine primary care providers to describe demographics, social vulnerability, and reasons for requesting advanced provision of medications. We used zip code to determine county-level four-point CDC Social Vulnerability Index.


      Among 160 people included in the study, requests for medications came from people living in 17 US states, the District of Columbia, and active-duty military. Nearly one-quarter came from California (24%); 16% came from New York, and less than 10% came from each of the remaining locations. The median age was 29 (IQR, 23–35; range 16–47 years). Most patients were childless (84%), and nearly half had either high or medium-high social vulnerability (23% and 26%, respectively). The most common reasons for requesting medications for future use included: personal choice (70%), future legal restrictions (55%), being comfortable at home (47%), privacy (46%), desire to take care of their own treatment (43%), and empowerment (42%). Some other common reasons included stigma (25%), cost (26%), work or school commitments (23%), and desire to keep it a secret (20%).


      Patients are requesting abortion medications in advance of confirmed pregnancy for a variety of reasons, even in states with fewer restrictive abortion laws. These results suggest that further research is needed to explore their actual use by these patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect